In breaking news released earlier this month, Cynata Therapeutics Limited (ASX: CYP) announced a major world first.
The company treated a patient with steroid resistant acute graft-versus-host disease (GvHD) as part of a phase 1 clinical study of its first mesenchymal stem cell (MSC) product, CYP-001 .
Click here for the full ASX announcement: http://cynata.com/wp-content/uploads/2017/05/17.05.16.Treatment-Commences-in-Cynatas-World-First-Clinical-Trial.pdf
This is an important value catalyst for Cynata and also for the regenerative medicine industry, because it is the first time ever that a patient has been treated with an allogeneic induced pluripotent stem cell (iPSC)-derived therapeutic mesenchymal stem cell (MSC) product.
The milestone also represents a giant leap forward in the production of MSCs, which is currently expensive, requires multiple extractions from different donors and relies on excessive expansion (division) of the cells to manufacture sufficient product. Cynata’s unique and proprietary Cymerus™ technology provides a completely different approach.
The Phase 1 clinical trial is expected to include a total of 16 patients who will receive two infusions of CYP-001, with a week between doses.
Insights from the Chief Investigator of Cynata’s GvHD Clinical Trial
Below is a fascinating interview with Dr. Adrian Bloor, UK Chief Investigator in Cynata Therapeutics’ (ASX: CYP) Phase 1 clinical trial in acute steroid resistant GvHD. In this webcast, he shares insights into the treatment of patients using Cynata’s CymerusTM product, a key global event in the history of stem cell therapeutics.
Dr. Bloor also explains the CymerusTM technology platform, which has the ability to create a stable clinical trial product using induced pluripotent stem cells sourced from a blood donation from a single donor. To date, MSC clinical trials have traditionally struggled with clinical endpoints and demonstrated variable results, because they rely on a massively expanded cellular product and require sourcing from multiple donors.
Learn more from Dr. Adrian Bloor, UK Chief Investigator of Cynata’s GvHD Clinical Trial, in the video below.